Antipsychotic drug action: targets for drug discovery with neurochemical imaging

References

• Acton PD. Nuclear Medicine In Clinical Diagnosis and Treatment. Ell PJ, Murray IPC (Eds). Churchill Livingstone, London, UK (1994).
   Google Scholar
• Bartels SJ, Clark RE, Peacock WJ, Dums AR, Pratt SI. Medicare and medicaid costs for schizophrenia patients by age cohort compared with costs for depression, dementia, and medically ill patients. Am. J. Geriatr. Psychiatry 11(6), 648–657 (2003).
   PubMed Web of Science ®Google Scholar
• Shen WW. A history of antipsychotic drug development. Compr. Psych. 40(6), 407–414 (1999).
   PubMed Web of Science ®Google Scholar
• Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483 (1976).
   PubMed Web of Science ®Google Scholar
• Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217–1219 (1975).
   PubMed Web of Science ®Google Scholar
• Bischoff S. Limbic selective neuroleptics. Clin. Neuropharmacol. 15(Suppl. 1), 265A–266A (1992).
   Google Scholar
• Meltzer HY. New drugs for the treatment of schizophrenia. Psychiatr. Clin. North Am. 16, 365–385 (1993).
   Google Scholar
• Scatton B, Zivkovic B. Neuroleptics and the limbic system. In: Psychopharmacology of the Limbic System. Trimble MR, Zarifian E (Eds). Oxford University Press, Oxford, UK, 174–197 (1985).
   Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psych. 45(9), 789–796 (1988).
   PubMed Web of Science ®Google Scholar
• Wolkin A, Barouche F, Wolf AP et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J. Psych. 146(7), 905–908 (1989).
   PubMed Web of Science ®Google Scholar
• Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol. Med. 23(3), 791–797 (1993).
   PubMedGoogle Scholar
• Nordstrom AL, Farde L, Wiesel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psych. 33(4), 227–235 (1993).
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psych. 157(4), 514–520 (2000).
   PubMed Web of Science ®Google Scholar
• Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340(8813), 199–202 (1992).
   PubMed Web of Science ®Google Scholar
• Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psych. 49(7), 538–544 (1992).
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin 2 and dopamine 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 25(3), 390–392 (1989).
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Farde L, Halldin C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl.)110(3), 365–367 (1993).
   PubMed Web of Science ®Google Scholar
• Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl.)110(3), 265–272 (1993).
   PubMed Web of Science ®Google Scholar
• Travis MJ, Busatto GF, Pilowsky LS et al. Serotonin: 5-HT2A receptor occupancy in vivo and response to the new antipsychotics olanzapine and sertindole. Br. J. Psych. 171, 290–291 (1997).
   PubMedGoogle Scholar
• Travis MJ, Busatto GF, Pilowsky LS et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br. J. Psych. 173, 236–241 (1998).
   PubMed Web of Science ®Google Scholar
• Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am. J. Psychiatry 155(4), 505–508 (1998).
   PubMedGoogle Scholar
• Schotte A, Janssen PF, Gommeren W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124(1–2), 57–73 (1996).
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psych. 156(2), 286–293 (1999).
   PubMed Web of Science ®Google Scholar
• de Paulis T. M-100907 (Aventis). Curr. Opin. Investig. Drugs. 2(1), 123–132 (2001).
   PubMedGoogle Scholar
• Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet 350(9076), 490–491 (1997).
   PubMed Web of Science ®Google Scholar
• Xiberas X, Martinot JL, Mallet L et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br. J. Psychiatry 179, 503–508 (2001).
   PubMed Web of Science ®Google Scholar
• Kessler RM, Ansari MS, Li R, Dawant B, Lee M, Meltzer HY. Occupancy of striatal and extrastriatal dopamine D2 receptors by atypical antipsychotic drugs. J. Nucl. Med. 43, 15 (2002).
   PubMedGoogle Scholar
• Bigliani V, Mulligan RS, Acton PD et al. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride SPET study. Psychopharmacology 150, 132–140 (2000).
   PubMedGoogle Scholar
• Stephenson CM, Bigliani V, Jones HM et al. Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo: [123I]-epidepride single photon emission tomography (SPET) study. Br. J. Psych. 177, 408–415 (2000).
   PubMedGoogle Scholar
• Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J. Clin. Psychopharmacol. 23(1), 5–14 (2003).
   PubMedGoogle Scholar
• Bressan RA, Erlandsson K, Jones HM et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am. J. Psych. 160, 1413–1420 (2003).
   PubMedGoogle Scholar
• Farde L, Suhara T, Nyberg S et al. A PET study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133, 396–404 (1997).
   PubMed Web of Science ®Google Scholar
• Talvik M, Nordström AL, Nyberg S, Olsson H, Halldin C, Farde L. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am. J. Psych. 158(6), 926–930 (2001).
   PubMed Web of Science ®Google Scholar
• Erlandsson K, Bressan RA, Mulligan RS, Ell PJ, Cunningham VJ, Pilowsky LS. Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings. Neuroimage 19, 1205–1214 (2003).
   PubMedGoogle Scholar
• Gründer G, Landvogt L, Vernaleken I et al. Beyond the striatum: clozapine’s striatal and extrastriatal binding characteristics. Neuroimage 22(Suppl. 2), T177–T178 (2004).
   Google Scholar
• Agid O, Mamo D, Zipursky RB, Vitcu I, Barsoum P, Kapur S. Differentiating the roles of striatal vs. extrastriatal dopamine D2 receptors in antipsychotic response –a PET study. Schizophr. Bull. 31(2), 442 (2005).
   Google Scholar
• Joel D, Weiner I. The connections of the primate subthalamic nucleus: indirect pathways and the open-interconnected scheme of basal gangliathalamocortical circuitry. Brain Res. Brain Res. Rev. 23, 62–78 (1997).
   PubMedGoogle Scholar
• Joyce JN, Meador-Woodruff JH. Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology 16, 375–384 (1997).
   PubMed Web of Science ®Google Scholar
• Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90, 231–259 (2001).
   PubMedGoogle Scholar
• Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res. Brain Res. Rev.31, 236–250 (2000).
   PubMed Web of Science ®Google Scholar
• Stone JM, Bressan RA, Erlandsson K, Ell PJ, Pilowsky LS. Non-uniform blockade of intrastriatal D(2)/D(3) receptors by risperidone and amisulpride. Psychopharmacology (Berl). 180(4), 664–669 (2005) [Epub ahead of print].
   Google Scholar
• Wilson JM, Sanyal S, Van Tol HH. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Eur. J. Pharmacol. 351(3), 273–286 (1998).
   PubMed Web of Science ®Google Scholar
• Seeman P, Guan HC, Van Tol HH. Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride. Eur. J. Pharmacol. 286(2), R3–R5 (1995).
   PubMed Web of Science ®Google Scholar
• Schoots O, Seeman P, Guan HC, Paterson AD, Van Tol HH. Long-term haloperidol elevates dopamine D4 receptors by 2-fold in rats. Eur. J. Pharmacol. 289(1), 67–72 (1995).
   PubMedGoogle Scholar
• Kusumi I, Ishikane T, Matsubara S, Koyama T. Long-term treatment with haloperidol or clozapine does not affect dopamine D4 receptors in rat frontal cortex. J. Neural Transm. Gen. Sect. 101(1–3), 231–235 (1995).
   PubMedGoogle Scholar
• Tarazi FI, Zhang K, Baldessarini RJ. Dopamine D4 receptors: beyond schizophrenia. J. Recept. Signal Transduct. Res. 3, 131–147 (2004).
   PubMedGoogle Scholar
• Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today 10(13), 917–925 (2005).
   PubMed Web of Science ®Google Scholar
• Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psych. 50(11), 873–883 (2001).
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psych. (3), 360–369 (2001).
   PubMedGoogle Scholar
• Walsh FX, Stevens TJ, Langlais PJ, Bird ED. Dopamine and homovanillic acid concentrations in striatal and limbic regions of human brain. Ann. Neurol. 12(1), 52–55 (1982).
   PubMedGoogle Scholar
• Bolonna AA, Kerwin RW. Partial agonism and schizophrenia. Br. J. Psych. 186, 7–10 (2005).
   PubMed Web of Science ®Google Scholar
• Ohlsen RI, Pilowsky LS. The place of partial agonism in psychiatry: recent developments. J. Psychopharmacol.19(4), 408–413 (2005).
   PubMed Web of Science ®Google Scholar
• Yokoi F, Grunder G, Biziere K et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27(2), 248–259 (2002).
   PubMed Web of Science ®Google Scholar
• Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev. Neurother. 5(3), 297–307 (2005).
   PubMedGoogle Scholar
• Ramaswamy S, Vijay D, William M, Sattar SP, Praveen F, Petty F. Aripiprazole possibly worsens psychosis. Int. Clin. Psychopharmacol. 19(1), 45–48 (2004).
   PubMed Web of Science ®Google Scholar
• El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2, CD004578 (2004).
   PubMedGoogle Scholar
• Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modeling schizophrenia. Curr. Opin. Pharmacol. 5, 101–106 (2005).
   PubMed Web of Science ®Google Scholar
• Bressan RA, Erlandsson K, Stone JM et al. Impact of schizophrenia and chronic antipsychotic treatment on [(123)I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biol. Psychiatry 58(1), 41–46 (2005).
   PubMedGoogle Scholar
• Bressan RA, Erlandsson K, Mulligan RS et al. NMDA dysfunction in schizophrenia is modulated by antipsychotic drugs: a [123I]CNS 1261 study. Neuroimage 22(Suppl. 2), T103 (2004).
   Google Scholar
• Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 72(2–3), 225–234 (2005).
   PubMed Web of Science ®Google Scholar
• Rowland LM, Bustillo JR, Mullins PG et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am. J. Psych. 162(2), 394–396 (2005).
   PubMed Web of Science ®Google Scholar
• Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psych. 52(12), 998–1007 (1995).
   PubMed Web of Science ®Google Scholar
• Theberge J, Bartha R, Drost DJ et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 159(11), 1944–1946 (2002).
   PubMed Web of Science ®Google Scholar
• Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am. J. Psychiatry 161(6), 1116–1118 (2004).
   PubMedGoogle Scholar
• Theberge J, Al-Semaan Y, Williamson PC et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am. J. Psychiatry 160(12), 2231–2233 (2003).
   PubMed Web of Science ®Google Scholar
• Pantelis C, Velakoulis D, McGorry PD et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361(9354), 281–288 (2003).
   PubMed Web of Science ®Google Scholar
• Coyle JT. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem. Pharmacol. 68(8), 1507–1514 (2004).
   PubMed Web of Science ®Google Scholar
• Ripoll N, Bronnec M, Bourin M. Nicotinic receptors and schizophrenia. Curr. Med. Res. Opin. 20(7), 1057–1074 (2004).
   PubMed Web of Science ®Google Scholar
• Domino EF, Mirzoyan D, Tsukada H. N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (5), 801–811 (2004).
   PubMed Web of Science ®Google Scholar
• Levin ED, Petro A, Caldwell DP. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(4), 581–586 (2005).
   PubMedGoogle Scholar
• Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY. N-Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M(1) muscarinic receptors. Neuropsychopharmacology (2005) [Epub ahead of print].
   Google Scholar
• Tandon R. Cholinergic aspects of schizophrenia. Br. J. Psychiatry 37(Suppl.) 7–11 (1999).
   Google Scholar
• Sur C, Mallorga PJ, Wittmann M et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl Acad. Sci. USA 100(23), 13674–13679 (2003).
   PubMed Web of Science ®Google Scholar
• Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. Eur. J. Neurosci. 9, 2887–2895 (1998).
   PubMedGoogle Scholar
• Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. USA 95(19), 11465–11470 (1998).
   PubMedGoogle Scholar
• Raedler TJ, Knable MB, Jones DW et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am. J. Psychiatry 160(1), 118–127 (2003).
   PubMed Web of Science ®Google Scholar
• Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 28(8), 1531–1537 (2003).
   PubMed Web of Science ®Google Scholar
• Raedler TJ, Knable MB, Jones DW et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 23(1), 56–68 (2000).
   PubMed Web of Science ®Google Scholar
• Crook JM, Dean B, Pavey G, Copolov D. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci. 64(19), 1761–1771 (1999).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Shannon HE, Rasmussen K et al. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicycloKaran RS. Brain Res. 795, 179–190 (1998).
   PubMedGoogle Scholar
• Ravishankar P, Pandhi P. Effect of muscarinic receptor agonists on animal models of psychosis. Methods Find. Exp. Clin. Pharmacol. 22(3), 169–172 (2000).
   PubMedGoogle Scholar
• Stanhope KJ, Mirza NR, Bickerdike MJ et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J. Pharmacol. Exp. Ther. 299(2), 782–792 (2001).
   PubMedGoogle Scholar
• Andersen MB, Fink-Jensen A, Peacock L et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in cebus apella monkeys. Neuropsychopharmacology 28(6), 1168–1175 (2003).
   PubMed Web of Science ®Google Scholar
• Wirkner K, Krause T, Koles L, Thummler S, Al-Khrasani M, Illes P. D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-D-aspartate currents in the rat prefrontal cortex. Neurosci. Lett. 372(1–2), 89–93 (2004).
   PubMedGoogle Scholar
• Tauscher J, Hussain T, Agid O et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry 161(9), 1620–1625 (2004).
   PubMed Web of Science ®Google Scholar
• Okubo Y, Suhara T, Suzuki K et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385(6617), 634–636 (1997).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Mawlawi O, Lombardo I et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22(9), 3708–3719 (2002).
   PubMed Web of Science ®Google Scholar
• Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am. J. Psychiatry 159(5), 761–767 (2002).
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 174(1), 3–16 (2004).
   PubMedGoogle Scholar
• Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel FA. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl.) 121(3), 309–316 (1995).
   PubMed Web of Science ®Google Scholar
• Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(7), 1081–1090 (2003).
   PubMed Web of Science ®Google Scholar
• Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361(9369), 1581–1589 (2003).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar